A 2-year update phase II ALTA trial confirmed durable high activity against BM by brigatinib in 222 patients with ALK+ NSCLC who progressed to crizotinib treatment randomized to two different dose regimens: arm A, 90 mg daily, and arm B, 90 mg daily for a week followed by 180 mg daily. The gene discussed is ALK; the disease is non-small cell lung carcinoma.